Lazzari Chiara, Mirabile Aurora, Bulotta Alessandra, Viganó Maria Grazia, Ogliari Francesca Rita, Ippati Stefania, DellOca Italo, Santarpia Mariacarmela, Lorusso Vincenza, Reck Martin, Gregorc Vanesa
Department of Oncology, IRCCS San Raffaele Hospital, via Olgettina 60, 20132 Milano, Italy.
Department of Radiotherapy, IRCSS San Raffaele Hospital, via Olgettina 60, 20132 Milano, Italy.
Cancers (Basel). 2021 Feb 27;13(5):998. doi: 10.3390/cancers13050998.
Several trials have tried for decades to improve the outcome of extensive disease small cell lung cancer (ED-SCLC) through attempts to modify the standard treatments. Nevertheless, platinum/etoposide combination and topotecan have remained respectively the first and the second line standard treatments for the last 40 years. With the advent of immunotherapy, this scenario has finally changed. Our review aims to provide an overview of the primary studies on the actual therapeutic strategies available for ED-SCLC patients, and to highlight emerging evidence supporting the use of immunotherapy in SCLC patients.
几十年来,多项试验试图通过改进标准治疗方法来改善广泛期小细胞肺癌(ED-SCLC)的治疗结果。然而,在过去40年里,铂类/依托泊苷联合方案和拓扑替康分别一直是一线和二线标准治疗方案。随着免疫疗法的出现,这种情况终于发生了改变。我们的综述旨在概述关于ED-SCLC患者现有实际治疗策略的主要研究,并强调支持在SCLC患者中使用免疫疗法的新证据。